Triple GLP-1 Agonist vs Amylin Analog | Research Comparison
Retatrutide vs Cagrilintide
A research comparison of retatrutide (GLP-1/GIP/glucagon triple agonist) and cagrilintide (long-acting amylin analog). Two distinct mechanisms for studying the frontier of multi-receptor metabolic peptide research — and the scientific rationale for the emerging CariSema + glucagon co-activation research space.
Retatrutide targets GLP-1R/GIPR/GCGR through a single modified peptide scaffold. Cagrilintide targets AMY1-3R through a separate receptor system entirely. Their mechanisms do not overlap — making them the ideal pair for exploring maximal multi-pathway metabolic research. When combined with semaglutide as a third control, you cover four distinct receptor systems (GLP-1R, GIPR, GCGR, AMY1-3R) from three compounds.
| Parameter | Retatrutide | Cagrilintide |
|---|---|---|
| Receptor System | GLP-1R / GIPR / GCGR | AMY1-3R (amylin) |
| Receptor Generation | 3rd gen triple agonist | Amylin class |
| CNS Target | Hypothalamus, VMH | Area postrema, NTS |
| Glucagon Effect | GCGR agonism (unique) | Glucagon suppression |
| Insulin Secretion | GLP-1R/GIPR mediated | Amylin-mediated indirect |
| Hepatic Effect | GCGR-driven lipolysis | Minimal direct effect |
| Gastric Emptying | Strong inhibition | Moderate inhibition |
| Half-Life | ~6 days | ~7 days |
| MW | 4,731 Da | 3,894 Da |
| Price | See price | See price |
| HPLC Purity | Not published | Not published |
Mechanistic Comparison — Three Receptors vs One Family
Retatrutide is the most receptor-broad single metabolic peptide in current preclinical research. Its modified peptide scaffold simultaneously engages GLP-1R (Gαs/cAMP/PKA), GIPR (Gαs/cAMP with adipose-specific GIPR-β-arrestin coupling), and GCGR (Gαs/cAMP with strong hepatic and adipose expression). The GCGR component distinguishes retatrutide from all GLP-1/GIP dual agonists — glucagon receptor activation drives hepatic lipid oxidation, thermogenesis, and lipolysis through pathways entirely absent in tirzepatide or semaglutide.
Cagrilintide occupies a completely separate receptor universe. Amylin receptors (AMY1R, AMY2R, AMY3R) are heterodimers of calcitonin receptor (CTR) with RAMP1, RAMP2, or RAMP3 respectively. These receptors are highly expressed in the area postrema and nucleus tractus solitarius — brainstem regions critical for satiety signaling, nausea mediation, and glucoregulation — but largely absent from the hypothalamic and hepatic circuits that GLP-1R, GIPR, and GCGR primarily engage.
Four-receptor research model: Retatrutide + Cagrilintide + Semaglutide (as GLP-1R-only baseline) gives researchers access to GLP-1R, GIPR, GCGR, and AMY1-3R as independent variables in a single study design — spanning essentially the entire metabolic GPCR research space with three compounds.
GCGR Agonism — The Retatrutide Differentiator
The glucagon receptor (GCGR) component is the primary mechanistic differentiator between retatrutide and all other GLP-1 class compounds. Glucagon receptor activation increases hepatic glucose production and lipolysis — effects that in isolation would be metabolically counterproductive. But in the context of simultaneous GLP-1R-mediated insulin potentiation and GIP receptor co-activation, GCGR agonism is proposed to drive thermogenesis and hepatic fat oxidation without net glycemic impairment.
Retatrutide carries the broadest receptor coverage in this class — GLP-1R, GIPR and GCGR — which is the basis for its use as a reference agonist in multi-pathway metabolic study designs.
Multi-Receptor Research Strategy
For researchers designing the most comprehensive metabolic peptide research panel possible, the retatrutide + cagrilintide combination (with semaglutide as GLP-1R-only control) provides:
- Semaglutide: GLP-1R baseline — pure single-receptor incretin signal
- Tirzepatide: GLP-1R + GIPR — quantifies GIP co-activation delta
- Retatrutide: GLP-1R + GIPR + GCGR — quantifies GCGR co-activation delta above tirzepatide
- Cagrilintide: AMY1-3R — entirely separate receptor system, quantifies amylin pathway contribution
- Cagrilintide + Semaglutide: Models CagriSema dual-pathway mechanism
This five-condition design — three GLP-1 generation controls plus one amylin arm plus one combination arm — covers essentially the full current clinical research space for metabolic peptide pharmacology in a single study framework.
Research Use Only: All compounds are strictly for laboratory and in vitro research. Not for human use, veterinary use, or any diagnostic or treatment purpose. OligoPoly Laboratories supplies research-grade peptides exclusively to qualified researchers.
OligoPoly Laboratories — Houston TX · Research Use Only
Retatrutide vs Cagrilintide — Triple Agonist vs Amylin Receptor Research
Retatrutide (GLP-1R/GIPR/GCGR triple agonist, See price) and cagrilintide (AMY1-3R amylin analog, See price) are mechanistically orthogonal metabolic research peptides targeting entirely separate receptor systems. Their combination — alongside semaglutide and tirzepatide as GLP-1 class controls — enables researchers to cover four distinct metabolic GPCR systems from three compounds. OligoPoly Laboratories supplies both for laboratory research use from Houston TX.
Research Use Only.
Single-Compound Research Materials Referenced in This Guide
For Research Use Only · Third-Party Tested · COA Documentation · Ships from Houston TX